Bayer Kogenate FS

Attention: Your browser does not support Javascript, or Javascript support has been disabled. This web site utilizes the latest Internet technology, and in order to experience the full functionality of this web site you will need to ensure that Javascript is enabled.















































	General Conditions of Use Privacy Statement Imprint

	This website is intended for U.S. Audiences Only.

	© 2008 Bayer HealthCare LLC BAYER, the Bayer Cross, and Kogenate are registered trademarks of Bayer BIO-SET is a trademark of Biodome SAS

Bayer Resources

PEP

Parents Empowering Parents (PEP) is an innovative peer-to-peer skills program that introduces parents to the tools they need to handle the realities of raising a child with a bleeding disorder. The program has been funded with an unrestricted educational grant by Bayer since 1995.

The PEP program is presented to parents by parents of children with bleeding disorders, in tandem with social workers and nurses. This team approach combines the strengths of peer support with professional expertise.

To find out if there is a PEP program in your area, or for more information about bringing PEP to your treatment center, please call 212.229.8476, e-mail cmiller@ccapr.com, or log onto www.PEPprogram.org

Hemophilia Basics

Publications

EZ-Log

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.